(S)-2-((S)-3-(1H-Imidazol-5-yl)-2-(2-palmitamidoacetamido)propanamido)-6-aminohexanoic acid

Catalog No. :
ACUPDE812
CAS No. :
147732-56-7
Molecular Formula :
C30H54N6O5
Molecular Weight :
578.80

IUPAC Name:palmitoylglycyl-L-histidyl-L-lysine

(S)-2-((S)-3-(1H-Imidazol-5-yl)-2-(2-palmitamidoacetamido)propanamido)-6-aminohexanoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$113.00Login to see priceInquiryInquiry
1g97%$282.00Login to see priceInquiryInquiry
5g97%$845.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-2-((S)-3-(1H-Imidazol-5-yl)-2-(2-palmitamidoacetamido)propanamido)-6-aminohexanoic acid
IUPAC Namepalmitoylglycyl-L-histidyl-L-lysine
MDL No.MFCD18251733
Molecular FormulaC30H54N6O5
Molecular Weight578.80
SMILESO=C(O)[C@@H](NC([C@@H](NC(CNC(CCCCCCCCCCCCCCC)=O)=O)CC1=CN=CN1)=O)CCCCN
InChI KeyBYUQATUKPXLFLZ-UIOOFZCWSA-N
SynonymL-Lysine, N-(1-oxohexadecyl)glycyl-L-histidyl-;Palmitoyl Tripeptide-1Pal-AHK;N2-[(N-Palmitoylglycyl)-L-histidyl]-L-lysine;Pal-GHK(PalMitoyl Tripeptide-1);N-(1-Oxohexadecyl)glycyl-L-histidyl-L-lysine;N2-[N-[N-(1-oxohexadecyl)glycyl]-L-histidyl]-L-lysine;PalMitoyl Tripeptide-1、3;Pal-GHK, >=95%
CAS No.147732-56-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACUPDE812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUPDE812 route product structure diagram
    ACUPDE812147732-56-7
Inquiry

2. ACUPDE812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUPDE812 route product structure diagram
    ACUPDE812147732-56-7
Inquiry

Comments (0)